Drug Enforcement Administration August 14, 2024 – Federal Register Recent Federal Regulation Documents

Irene Kimura, M.D.; Decision and Order
Document Number: 2024-18100
Type: Notice
Date: 2024-08-14
Agency: Drug Enforcement Administration, Department of Justice
Thomas M. Fausset, O.D.; Decision and Order
Document Number: 2024-18096
Type: Notice
Date: 2024-08-14
Agency: Drug Enforcement Administration, Department of Justice
Robert Rowen, M.D.; Decision and Order
Document Number: 2024-18095
Type: Notice
Date: 2024-08-14
Agency: Drug Enforcement Administration, Department of Justice
Michael L. Brodie, M.D.; Decision and Order
Document Number: 2024-18094
Type: Notice
Date: 2024-08-14
Agency: Drug Enforcement Administration, Department of Justice
Schedules of Controlled Substances: Placement of Zuranolone in Schedule IV
Document Number: 2024-18087
Type: Rule
Date: 2024-08-14
Agency: Drug Enforcement Administration, Department of Justice
This final rule adopts, without change, an interim final rule with request for comments published in the Federal Register on October 31, 2023, placing zuranolone (chemically known as 1-[2- [(3R,5R,8R,9R,10S,13S,14S,17S)-3-hydroxy-3,13-dimethyl- 2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H- cyclopenta[a]phenanthren-17-yl]-2-oxoethyl]pyrazole-4-carboni trile) and its salts in schedule IV of the Controlled Substances Act. With the issuance of this final rule, the Drug Enforcement Administration maintains zuranolone, including its salts, in schedule IV of the Controlled Substances Act.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.